<DOC>
	<DOCNO>NCT02401542</DOCNO>
	<brief_summary>This Phase 1b/2 , randomize , double-blind , placebo-controlled , multicenter , parallel-group study B-701 plus docetaxel versus placebo plus docetaxel treatment locally advance metastatic urothelial cell carcinoma subject relapse , refractory standard therapy .</brief_summary>
	<brief_title>A Phase 1b/2 Study B-701 Treatment Locally Advanced Metastatic Urothelial Cell Carcinoma</brief_title>
	<detailed_description>This Phase 1b/2 , randomize , double-blind , placebo-controlled , multicenter , parallel-group , efficacy safety study B-701 plus docetaxel versus placebo plus docetaxel treatment subject Stage IV , locally advanced metastatic UCC relapse , refractory least one prior line chemotherapy . This study divide 2 phase : Lead-In Phase Randomized Phase ; Lead-In Phase divide 3 cohort . In Cohorts 1 2 , subject receive B-701 plus docetaxel . In Cohort 3 , subject receive B-701 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Key Provide tumor tissue obtain within 18 month enrollment suitable quality quantity demonstrate FGFR3 positive tumor IHC . For subject participate Randomized Phase , suitable archival tissue unavailable , core biopsy tumor tissue ( metastatic primary ) must obtain prior randomization Stage IV , locally advanced metastatic urothelial bladder cancer transitional cell carcinoma arise another location urinary tract , include urethra , ureter , renal pelvis Relapsed refractory one two prior line chemotherapy include taxane platinum agent , long platinum agent contraindicate subject ( i.e. , platinum agent contraindicate subject , one two prior regimen need include platinum agent ) Measurable disease accord RECIST v1.1 criterion â‰¥ 18 year old ECOG 0 1 Main Prior anticancer therapy within 4 week prior Cycle 1 , Day 1 Weight &gt; 100kg Clinically significant comorbid medical condition lab abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Urothelial Cell Carcinoma</keyword>
	<keyword>UCC</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>B-701</keyword>
	<keyword>FGFR3</keyword>
	<keyword>invasive bladder cancer</keyword>
	<keyword>target therapy</keyword>
	<keyword>Transitional Cell Carcinoma</keyword>
	<keyword>TCC</keyword>
	<keyword>Phase 2</keyword>
	<keyword>second line therapy</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>docetaxel</keyword>
	<keyword>combination therapy</keyword>
	<keyword>Phase 1</keyword>
</DOC>